ruxolitinib
Orphan DrugFDA Approved
Description
Ruxolitinib is a selective JAK1/JAK2 inhibitor approved for steroid-refractory acute and chronic graft-versus-host disease. It modulates inflammatory cytokine signaling that drives GVHD pathology. The drug has shown efficacy in both adult and pediatric patients with inadequate response to corticosteroids.
Indications & Therapeutic Use
acute graft-versus-host disease, chronic graft-versus-host disease, myelofibrosis, polycythemia vera
Global Availability (11 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
ruxolitinib
| Generic Name | ruxolitinib |
| Brands | 1 brand available |
| Active Ingredient | ruxolitinib phosphate |
| Drug Class | acute graft-versus-host disease |
| Manufacturer | Incyte Corporation |
| Dosage Forms | Oral tablet, 5mg, 10mg, 15mg, 20mg, 25mg; Topical cream 1.5% |
| Medical Code | L01EJ01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00934544 |
| Countries | 11 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations12 Validated Nodes